<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        13-475-08
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2008
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        MIMPARA 30MG F.C. TABLETS
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CINACALCET
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        707.6
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="PATHEON" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            PATHEON
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            AMGEN EUROPE B.V.
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        H05BX01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Mimpara works by controlling the levels of parathyroid hormone (PTH), calcium and phosphorous in your body. It is used to treat problems with organs called parathyroid glands. The parathyroids are four small glands in the neck, near the thyroid gland, that produce parathyroid hormone (PTH).</p><p>&nbsp;</p><p>Mimpara is used in adults:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to treat secondary hyperparathyroidism in adults with serious kidney disease who need dialysis to clear their blood of waste products.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to reduce high levels of calcium in the blood (hypercalcaemia) in adult patients with parathyroid cancer.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to reduce high levels of calcium in the blood (hypercalcaemia) in adult patients with primary hyperparathyroidism when removal of the gland is not possible.</p><p>&nbsp;</p><p>&nbsp;</p><p>In primary and secondary hyperparathyroidism too much PTH is produced by the parathyroid glands. &ldquo;Primary&rdquo; means that the hyperparathyroidism is not caused by any other condition and &ldquo;secondary&rdquo; means that the hyperparathyroidism is caused by another condition, e.g. kidney disease. Both primary and secondary hyperparathyroidism can cause the loss of calcium in the bones, which can lead to bone pain and fractures, problems with blood and heart vessels, kidney stones, mental illness and coma.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Mimpara</strong> if you are allergic to cinacalcet or any of the other ingredients of this medicine (listed in section&nbsp;6).</p><p><strong>Do not take Mimpara</strong> if you have low levels of calcium in your blood. Your doctor will monitor your blood calcium levels.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor, pharmacist or nurse before taking Mimpara.</p><p>&nbsp;</p><p>Before you start taking Mimpara, tell your doctor if you have or have ever had:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>seizures</strong> (fits or convulsions). The risk of having seizures is higher if you have had them before;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>liver problems</strong>;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>heart failure.</strong></p><p><strong>&nbsp;</strong></p><p>Mimpara reduces calcium levels. Life threatening events and fatal outcomes associated with low calcium levels (hypocalcaemia) have been reported in adults and children treated with Mimpara.</p><p>&nbsp;</p><p>Please tell your doctor if you experience any of the following which may be signs of low calcium levels: spasms, twitches, or cramps in your muscles, or numbness or tingling in your fingers, toes or around your mouth or seizures, confusion or loss of consciousness while being treated with Mimpara.</p><p>&nbsp;</p><p>Low calcium levels can have an effect on your heart rhythm. Tell your doctor if you experience an unusually fast or pounding heart beat, if you have heart rhythm problems, or if you take medicines known to cause heart rhythm problems, while taking Mimpara.</p><p>&nbsp;</p><p>For additional information see section&nbsp;4.</p><p>&nbsp;</p><p>During treatment with Mimpara, tell your doctor:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you start or stop smoking, as this may affect the way Mimpara works.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>Children under the age of 18 must not take Mimpara.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Other medicines and Mimpara</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines particularly etelcalcetide or any other medicines that lower the level of calcium in your blood.</p><p>&nbsp;</p><p>You should not receive Mimpara together with etelcalcetide.</p><p>&nbsp;</p><p>Tell your doctor if you are taking the following medicines.</p><p>&nbsp;</p><p>Medicines such as these can affect how Mimpara works:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines used to treat <strong>skin</strong> and <strong>fungal infections</strong> (ketoconazole, itraconazole and voriconazole);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines used to treat <strong>bacterial infections</strong> (telithromycin, rifampicin and ciprofloxacin);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a medicine used to treat <strong>HIV </strong>infection and AIDS (ritonavir);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a medicine used to treat <strong>depression</strong> (fluvoxamine).</p><p>&nbsp;</p><p>Mimpara may affect how medicines such as the following work:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines used to treat <strong>depression</strong> (amitriptyline, desipramine, nortriptyline and clomipramine);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a medicine used to relieve <strong>cough</strong> (dextromethorphan);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines used to treat <strong>changes in heart rate</strong> (flecainide and propafenone);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a medicine used to treat <strong>high blood pressure</strong> (metoprolol).</p><p>&nbsp;</p><p><strong>Mimpara with food and drink</strong></p><p>Mimpara should be taken with or shortly after food.</p><p>&nbsp;</p><p><strong>Pregnancy, breast‑feeding and fertility</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>&nbsp;</p><p>Mimpara has not been tested in pregnant women. In case of pregnancy, your doctor may decide to modify your treatment, as Mimpara might harm the unborn baby.</p><p>&nbsp;</p><p>It is not known whether Mimpara is excreted in human milk. Your doctor will discuss with you if you should discontinue either breast‑feeding or treatment with Mimpara.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Dizziness and seizures have been reported by patients taking Mimpara. If you experience these side effects, do not drive or operate machines.</p><p>&nbsp;</p><p><strong>Mimpara contains lactose</strong></p><p>If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are unsure. Your doctor will tell you how much Mimpara you must take.</p><p>&nbsp;</p><p>Mimpara must be taken orally, with or shortly after food. The tablets must be taken whole and are not to be chewed, crushed or divided.</p><p>&nbsp;</p><p>Your doctor will take regular blood samples during treatment to monitor your progress and will adjust your dose if necessary.</p><p>&nbsp;</p><p><u>If you are being treated for secondary hyperparathyroidism</u></p><p>The usual starting dose for Mimpara in adults is 30&nbsp;mg (one tablet) once per day.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>If you are being treated for parathyroid cancer or primary hyperparathyroidism</u></p><p>The usual starting dose for Mimpara in adults is 30&nbsp;mg (one tablet) twice per day.</p><p>&nbsp;</p><p><strong>If you take more Mimpara than you should</strong></p><p>If you take more Mimpara than you should you must contact your doctor immediately. Possible signs of overdose include numbness or tingling around the mouth, muscle aches or cramps and seizures.</p><p>&nbsp;</p><p><strong>If you forget to take Mimpara</strong></p><p>Do not take a double dose to make up for a forgotten dose.</p><p>&nbsp;</p><p>If you have forgotten a dose of Mimpara, you should take your next dose as normal.</p><p><strong>&nbsp;</strong></p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>Please tell your doctor immediately:</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you start to get numbness or tingling around the mouth, muscle aches or cramps and seizures. These may be signs that your calcium levels are too low (hypocalcaemia).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you experience swelling of the face, lips, mouth, tongue or throat which may cause difficulty in swallowing or breathing (angioedema).</p><p>&nbsp;</p><p><strong>Very common: may affect more than 1 in 10 people</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nausea and vomiting, these side effects are normally quite mild and do not last for long.</p><p>&nbsp;</p><p><strong>Common: may affect up to 1 in 10 people</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; numbness or tingling sensation (paraesthesia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss (anorexia) or decrease of appetite</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle pain (myalgia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weakness (asthenia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reduced testosterone levels</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high potassium levels in the blood (hyperkalaemia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allergic reactions (hypersensitivity)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; seizures (convulsions or fits)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low blood pressure (hypotension)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; upper respiratory infection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; breathing difficulties (dyspnoea)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cough</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; indigestion (dyspepsia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abdominal pain, abdominal pain &ndash; upper</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; constipation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle spasms</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; back pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low calcium levels in the blood (hypocalcaemia).</p><p>&nbsp;</p><p><strong>Not known: frequency cannot be estimated from available data</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hives (urticaria)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of the face, lips, mouth, tongue or throat which may cause difficulty in swallowing or breathing (angioedema)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; unusually fast or pounding heart beat which may be associated with low levels of calcium in your blood (QT prolongation and ventricular arrhythmia secondary to hypocalcaemia).</p><p>&nbsp;</p><p>After taking Mimpara a very small number of patients with heart failure had worsening of their condition and/or low blood pressure (hypotension).</p><p>&nbsp;</p><p><strong>Children and adolescents </strong></p><p>Mimpara is not indicated for use in paediatric patients.</p><p>&nbsp;</p><p>A fatal outcome was reported in an adolescent clinical trial patient with very low calcium levels in the blood (hypocalcaemia).</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Do not store above 30&nbsp;&deg;C.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Mimpara contains</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is cinacalcet. Each film‑coated tablet contains 30&nbsp;mg, 60&nbsp;mg or 90&nbsp;mg of cinacalcet (as hydrochloride).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 30 mg: Pre‑gelatinised starch (maize) (12.02 mg), Microcrystalline cellulose (121.82 mg), Povidone (3.68 mg), Crospovidone (7.62 mg), Magnesium stearate (0.90 mg), Colloidal anhydrous silica (0.90 mg).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 60 mg: Pre‑gelatinised starch (maize) (24.04 mg), Microcrystalline cellulose (243.64 mg), Povidone (7.36 mg), Crospovidone (15.24 mg), Magnesium stearate (1.80 mg), Colloidal anhydrous silica (1.80 mg).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 90 mg: Pre‑gelatinised starch (maize) (36.06 mg), Microcrystalline cellulose (365.46 mg), Povidone (11.04 mg), Crospovidone (22.86 mg), Magnesium stearate (2.70 mg), Colloidal anhydrous silica (2.70 mg).</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The tablets are coated with:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Carnauba wax (30mg: 0.018 mg, 60mg: 0.036 mg, 90mg: 0.054 mg)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Opadry green (30mg: 7.20 mg, 60mg: 14.40 mg, 90mg: 21.60 mg) (containing lactose monohydrate, hypromellose, titanium dioxide (E171), glycerol triacetate, FD&amp;C Blue (E132), iron oxide yellow (E172))</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Opadry clear (30mg: 2.70 mg, 60mg: 5.40 mg, 90mg: 8.10 mg) (containing hypromellose, macrogol)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Mimpara is a light green film coated tablet. They are oval shaped and have “30”, “60” or “90” marked on one side and “AMG” on the other side.

30 mg tablets are approximately 9.7 mm long and 6.0 mm wide.
60 mg tablets are approximately 12.2 mm long and 7.6 mm wide.
90 mg tablets are approximately 13.9 mm long and 8.7 mm wide.

Mimpara is available in blisters of 30 mg, 60 mg or 90 mg film coated tablets. Each blister pack contains either 14, 28 or 84 tablets in a carton.

Not all pack sizes may be marketed.
Not all presentations may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder and Manufacturer:</strong></p><p>Amgen Europe B.V.</p><p>Minervum 7061</p><p>4817 ZK Breda</p><p>The Netherlands</p><p><strong>Site of Manufacture of Drug Product:</strong></p><p>Patheon Inc.,Toronto Region Operations</p><p>2100 Syntex Court,</p><p>Mississauga</p><p>Ontario,</p><p>L5N 7K9</p><p>Canada</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in August 2017.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يعمل ممبارا على ضبط مستوى هرمون الغدة الجار درقية (PTH&rlm;)&rlm;، الكالسيوم والفسفور في جسمك. ويعمل على معالجة المشاكل الخاصة بالأعضاء والتي تعرف بالغدد الجار درقية. الغدد الجار درقية هي عبارة عن أربع غدد صغيرة في العنق بالقرب من الغدد الدرقية وظيفتها إنتاج هرمون الغدد الجار الدرقية (PTH).</p><p>&nbsp;</p><p dir="RTL">يستخدم ممبارا لدى البالغين:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لمعالجة إفراط إفراز الغدة الجار درقية الثانوي لدى مرضى الفشل الكلوي الخطير من البالغين الذين يحتاجون الغسيل الكلوي لتنقية دمائهم من المواد الفاسدة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لتخفيض مستوى الكالسيوم المرتفع في الدم لدى مرضى سرطان الغدة الجار درقية من البالغين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لتخفيض مستوى الكالسيوم المرتفع في الدم لدى مرضى إفراط إفراز الغدة الجار درقية الأولي من البالغين عندما يكون استئصال الغدة الجار درقية لديهم غير ممكن.</p><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL">في حالة إفراط إفراز الغدة الجار درقية الأولي والثانوي، تفرز نسبة كبيرة من هرمون الغدة الجار درقية في الدم بواسطة الغدة الجار درقية. يعني &quot;الأولي&quot; أن إفراط إفراز الغدة الجار درقية ليس بسبب أي حالة أخرى أما &quot;الثانوي&quot; فيعني أن إفراط إفراز الغدة الجار درقية هو بسبب حالة أخرى مثل، مرض الكلى. يستطيع كل من إفراط إفراز الغدة الجاردرقية الأولي والثانوي أن يسبب فقدان الكالسيوم من العظام والذي يؤدي بدوره إلى آلام العظام وكسور ومشاكل في الأوعية الدموية والقلب، حصوات في الكلى، أمراض ذهنية وغيبوبة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول ممبارا</strong> إذا كنت تعاني من حساسية للسيناكالست أو أحد مكونات هذا الدواء (المدرجة في القسم&nbsp;٦).</p><p dir="RTL"><strong>لا تتناول ممبارا</strong> إذا كنت تعاني من مستويات منخفضة من الكالسيوم في الدم. سيراقب طبيبك مستويات الكالسيوم في الدم لديك.</p><p>&nbsp;</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL">تحدث إلى طبيبك، الصيدلي أو الممرضة قبل تناول ممبارا.</p><p>&nbsp;</p><p dir="RTL">قبل البدء بتناول ممبارا، أبلغ الطبيب إذا كنت تعاني من أي حالات مرضية سابقة أو حالية والتي تشمل :</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>حالات الصرع</strong> (النوبات أو التشنجات). إن خطورة التعرض للصرع أكبر عند المرضى الذين تعرضوا لمثل تلك الحالة من قبل؛</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>مشاكل الكبد</strong>؛</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>فشل القلب.</strong></p><p><strong>&nbsp;</strong></p><p dir="RTL">يساهم ممبارا في تخفيض مستويات الكالسيوم. لقد سجلت أحداث مهددة للحياة ونتائج مميتة مرتبطة بمستويات الكالسيوم المنخفضة (نقص الكالسيوم بالدم) لدى المرضى البالغين والأطفال الذين يخضعون للعلاج بممبارا.</p><p>&nbsp;</p><p dir="RTL">من فضلك أخبر طبيبك عند تعرضك لأي مما يلي والذي قد يعد علامات انخفاض مستوى الكالسيوم: تقلصات أو ارتجافات أو تشنج العضلات، أو تنميل أو خدر في أصابع يديك أو أصابع قدميك أو حول فمك أو تعرضك لنوبات أو ارتباك أو فقدان الوعي أثناء علاجك بممبارا.</p><p>&nbsp;</p><p dir="RTL">قد تؤثر مستويات الكالسيوم المنخفضة على نبضات قلبك. أخبر طبيبك إذا تعرضت إلى تسارع غير معتاد أوتصاعد لنبضات القلب، إذا كان لديك مشاكل بنبضات القلب، أو إذا كنت تتناول أدوية من المعروف أنها تسبب مشاكل بنبضات القلب بالتزامن مع تناول ممبارا.</p><p>&nbsp;</p><p dir="RTL">لمزيد من المعلومات انظر القسم ٤.</p><p>&nbsp;</p><p dir="RTL">أثناء تناولك ممبارا، أخبر طبيبك:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت بدأت أو أقلعت عن التدخين حيث قد يؤثر هذا على طريقة عمل ممبارا.</p><p>&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">يجب على الأطفال أقل من ۱۸ سنة ألا يتناولوا ممبارا.</p><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL"><strong>أدويــة أخـــرى وممبارا</strong></p><p dir="RTL">أخبر الطبيب أو الصيدلي إذا كنت تتناول أو تناولت حديثا أو قد تتناول أي أدوية أخرى خاصة إتلكالسيتيد أو أي أدوية أخرى تقلل مستويات الكالسيوم في الدم.</p><p>&nbsp;</p><p dir="RTL">يجب عليك أن لا تتناول ممبارا مع إتلكالسيتيد.</p><p>&nbsp;</p><p dir="RTL">أخبر طبيبك إذا كنت تتناول أحد الأدوية التالية.</p><p>&nbsp;</p><p dir="RTL">مثل هذه الأدوية قد تؤثر على طريقة عمل ممبارا :</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تستعمل لعلاج <strong>عدوى الجلد والفطريات</strong> (كيتوكونازول، اتراكونازول و فوريكونازول)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تستعمل في علاج <strong>العدوى البكتيرية</strong> (تليثروميسين، ريفامبيسين و سيبروفلوكساسين)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دواء يستعمل في علاج عدوى <strong>HIV</strong> والايدز (ريتونافير)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دواء يستعمل في علاج <strong>الاكتئاب</strong> (فلوفوكسامين)؛</p><p>&nbsp;</p><p dir="RTL">قد يؤثرممبارا على طريقة عمل الأدوية التالية :</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تستعمل في علاج <strong>الاكتئاب</strong> (اميتربتالين، ديسبرامين، نورتربتلين، كلوميبرامين)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دواء يستعمل في تخفيف <strong>الكحة</strong> (ديكستروميتورفان)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تستعمل في علاج <strong>تغير معدل ضربات القلب</strong> (فليكانيد، بروبافينون)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دواء يستعمل في علاج<strong> ضغط الدم المرتفع</strong> (ميتوبرولول)؛</p><p>&nbsp;</p><p dir="RTL"><strong>ممبارا مع الأطعمة والشراب</strong></p><p dir="RTL">يجب تناول ممبارا مع الطعام أو بعد تناول الطعام بفترة وجيزة.</p><p>&nbsp;</p><p dir="RTL"><strong>الحمل، الرضاعة الطبيعية والخصوبة</strong></p><p dir="RTL">إذا كنت حاملا أو ترضعين، تظنين أنك حاملا أو تخططين للحمل، اطلبي نصيحة طبيبك أو الصيدلي قبل أن تتناولي هذا الدواء.</p><p>&nbsp;</p><p dir="RTL">لم يتم اختبار ممبارا لدى الحوامل. في حالة الحمل، فقد يقرر الطبيب تعديل طريقة العلاج، إذ قد يؤذي ممبارا الطفل الذي لم يولد بعد.</p><p>&nbsp;</p><p dir="RTL">من غير المعروف إذا كان ممبارا يتم إفرازه في حليب الرضاعة الطبيعية. سوف يناقش معك طبيبك إذا كنت ستنقطعين عن الرضاعة الطبيعية أو العلاج بممبارا.</p><p>&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">سجلت حالات دوار ونوبات لدى المرضى الذين يتناولون ممبارا. إذا واجهت هذه الآثار الجانبية، توقف على الفور عن قيادة أو تشغيل الآلات.</p><p>&nbsp;</p><p dir="RTL"><strong>يحتوي ممبارا على اللاكتوز</strong></p><p dir="RTL">إذا أخبرك طبيبك انك لا تستطيع تحمل بعض السكريات، اتصل بطبيبك قبل تناولك هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">اتبع تعليمات طبيبك أو الصيدلي بخصوص تناول هذا الدواء. اسأل طبيبك أو الصيدلي إذا كنت غير متأكدا. سوف يخبرك طبيبك عن كمية ممبارا التي يجب تناولها.</p><p>&nbsp;</p><p dir="RTL">يجب تناول ممبارا عن طريق الفم، عند أو بعد تناول الطعام بفترة وجيزة، كما يجب تناول القرص كاملا دون مضغه أو جرشه أو تجزئته.</p><p>&nbsp;</p><p dir="RTL">سوف يأخذ طبيبك بانتظام عينة من الدم أثناء العلاج ليراقب تحسنك وسوف يعدل جرعتك إذا تطلب الأمر.</p><p>&nbsp;</p><p dir="RTL"><u>إذا كنت تعالج من زيادة إفراز هرمون الغدد الجار الدرقية الثانوي</u></p><p dir="RTL">إن الجرعة الأولية المعتادة لممبارا بالنسبة للبالغين هي ٣٠&nbsp;مجم (قرص واحد) مرة في اليوم.</p><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL"><u>إذا كنت تعالج من سرطان الغدد الجار درقية أو زيادة إفراز هرمون الغدة الجار درقية الأولي</u></p><p dir="RTL">إن الجرعة الأولية المعتادة لممبارا بالنسبة للبالغين هي٣٠&nbsp;مجم (قرص واحد) مرتين في اليوم.</p><p>&nbsp;</p><p dir="RTL"><strong>عند تناول كمية زائدة من ممبارا</strong></p><p dir="RTL">يجب مراجعة الطبيب فورا إذا تناولت جرعة ممبارا أكبر من الجرعة المحددة. تشمل الأعراض المحتملة من الجرعة الزائدة على تخدر أو وخز خفيف حول الفم، ألم بالعضلات أو تشنجات ونوبات.</p><p>&nbsp;</p><p dir="RTL"><strong>في حال نسيان تناول ممبارا</strong></p><p dir="RTL">لا تتناول جرعة مضاعفة لتعويض الجرعة المنسية.</p><p>&nbsp;</p><p dir="RTL">يجب تناول الجرعة التالية كالمعتاد إذا لم تتذكر تناول الجرعة في مواعيدها.</p><p><strong>&nbsp;</strong></p><p dir="RTL">للمزيد من الاستفسار حول كيفية تناول هذا الدواء، يرجى مراجعة الطبيب، الصيدلي أو الممرضة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">قد يسبب هذا الدواء كغيره من الأدوية آثارا جانبية، إلا أنها قد لا تصيب الجميع.</p><p>&nbsp;</p><p dir="RTL"><strong>من فضلك أخبر طبيبك على الفور:</strong></p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا بدأت الإحساس بتخدر ووخز خفيف حول الفم، ألم بالعضلات أو تشنجات ونوبات فقد يكون هذا أعراض بأن مستوى الكالسيوم لديك منخفض جدا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا تعرضت لتورم في الوجه أو الشفاه أو الفم أو اللسان أو الحلق والذي قد يتسبب في صعوبة البلع أو التنفس (الوذمة الوعائية).</p><p>&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية الشائعة جدا</strong> (قد تؤثر على أكثر من ١ عن كل ١٠&nbsp;أشخاص)</p><p dir="RTL"><strong><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></strong>مثل الغثيان والقيء، وعادة ما تكون تلك الأعراض طفيفة ولا تستمر لفترات طويلة.</p><p>&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية الشائعة</strong> (قد تؤثر على ١ عن كل ١٠&nbsp;أشخاص)</p><p dir="RTL"><strong><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></strong>الشعور بالدوار</p><p dir="RTL"><strong><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></strong>التنميل والشعور بالوخز</p><p dir="RTL"><strong><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></strong>فقدان أو نقص الشهية</p><p dir="RTL"><strong><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></strong>ألم بالعضلات</p><p dir="RTL"><strong><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></strong>الشعور بالضعف</p><p dir="RTL"><strong><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></strong>الحكة</p><p dir="RTL"><strong><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></strong>نقص مستويات هرمون التستوستيرون في الجسم</p><p dir="RTL"><strong><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></strong>ارتفاع مستويات البوتاسيوم في الدم (فرط بوتاسيوم الدم)</p><p dir="RTL"><strong><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></strong>تفاعلات حساسية (فرط التحسس)</p><p dir="RTL"><strong><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></strong>صداع</p><p dir="RTL"><strong><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></strong>حالات الصرع (النوبات أو التشنجات)</p><p dir="RTL"><strong><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></strong>انخفاض ضغط الدم</p><p dir="RTL"><strong><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></strong>عدوى الجهاز التنفسي العلوي</p><p dir="RTL"><strong><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></strong>صعوبة في التنفس</p><p dir="RTL"><strong><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></strong>سعال</p><p dir="RTL"><strong><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></strong>عسر الهضم</p><p dir="RTL"><strong><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></strong>إسهال</p><p dir="RTL"><strong><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></strong>ألم في البطن، آلام في أعلى البطن</p><p dir="RTL"><strong><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></strong>إمساك</p><p dir="RTL"><strong><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></strong>تقلص بالعضلات</p><p dir="RTL"><strong><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></strong>ألم بالظهر</p><p dir="RTL"><strong><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></strong>مستويات الكالسيوم منخفضة في الدم (نقص الكالسيوم بالدم)</p><p>&nbsp;</p><p dir="RTL"><strong>من غير المعروف: التكرار لا يمكن أن يقدر من البيانات المتاحة</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشرى (الارتكاريا)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم في الوجه، الشفاه، الفم، اللسان، أو الحلق الذي قد يؤدي لصعوبة في البلع أو التنفس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تسارع غير معتاد أو تصاعد لنبضات القلب والذي قد يترافق مع مستويات كالسيوم منخفضة في الدم (إطالة الفاصلة QT وعدم انتظام ضربات القلب البطيني الثانوية لنقص الكالسيوم في الدم).</p><p>&nbsp;</p><p dir="RTL">بعد تناول ممبارا، لوحظ لدى عدد قليل جدا من مرضى النوبات القلبية ازدياد حالتهم سوءا و/أو انخفاض ضغط الدم لديهم.</p><p>&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">لا يوصف ممبارا لدى المرضى الأطفال.</p><p>&nbsp;</p><p dir="RTL">ولقد سجلت نتيجة مميتة مرتبطة بمستويات كالسيوم منخفضة جدا في الدم (نقص الكالسيوم بالدم) لدى مريض مراهق خلال التجارب السريرية.</p><p>&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبیة</strong></p><p dir="RTL">إذا تعرضت لأي آثار جانبیة، یرجى إبلاغ طبیبك أو الصيدلي أو الممرضة. ویشمل ذلك أي آثار جانبیة غیر مدرجة في ھذه النشرة. من خلال الإبلاغ عن الآثار الجانبیة، یمكنك أن تساعد في توفیر مزید من المعلومات حول سلامة ھذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحفظ هذا الدواء بعيدا عن مرأى و متناول الأطفال.</p><p>&nbsp;</p><p dir="RTL">لا يجب استخدام هذا الدواء بعد انتهاء تاريخ الصلاحية المدون على العلبة و الغلاف القصديري بعد EXP. ويشير تاريخ انتهاء الصلاحية إلى آخر يوم من ذلك الشهر.</p><p>&nbsp;</p><p dir="RTL">لا تخزن فوق درجة حرارة ٣٠&nbsp;&deg;م.</p><p>&nbsp;</p><p dir="RTL">يجب عدم رمي الأدوية بالقرب من مياه الصرف أو الفضلات المنزلية، وعليك باستشارة الصيدلي عن كيفية التخلص من الأدوية التي لا تحتاجها، فمثل تلك الإجراءات تساعد في حماية البيئة.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن المادة الفعالة هي سيناكالست. ويحتوي كل قرص مغلف على ٣٠&nbsp;مجم، ٦٠&nbsp;مجم أو ٩٠&nbsp;مجم من سينا كالست (على شكل هيدروكلوريد).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ٣٠&nbsp;مجم: نشاء الذرة (١٢٫٠٢&nbsp;مجم)، كريستالين دقيق من السيليلوز (١٢١٫٨٢&nbsp;مجم)، بوفيدون (٣٫٦٨&nbsp;مجم)، كروسبوفيدون (٧٫٦٢&nbsp;مجم)، سترات الماغنزيوم (٠٫٩٠&nbsp;مجم)، سيليكا غروية لا مائية (٠٫٩٠&nbsp;مجم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ٦٠&nbsp;مجم: نشاء الذرة (٢٤٫٠٤&nbsp;مجم)، كريستالين دقيق من السيليلوز (٢٤٣٫٦٤&nbsp;مجم)، بوفيدون (٧٫٣٦&nbsp;مجم)، كروسبوفيدون (١٥٫٢٤&nbsp;مجم)، سترات الماغنزيوم (١٫٨٠&nbsp;مجم)، سيليكا غروية لا مائية (١٫٨٠&nbsp;مجم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ٩٠&nbsp;مجم: نشاء الذرة (٣٦٫٠٦&nbsp;مجم)، كريستالين دقيق من السيليلوز (٣٦٥٫٤٦&nbsp;مجم)، بوفيدون (١١٫٠٤&nbsp;مجم)، كروسبوفيدون (٢٢٫٨٦&nbsp;مجم)، سترات الماغنزيوم (٢٫٧٠&nbsp;مجم)، سيليكا غروية لا مائية (٢٫٧٠&nbsp;مجم).</p><p>&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغلف الأقراص بواسطة:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شمع كارنوبا (٣٠&nbsp;مجم: ٠٫٠١٨&nbsp;مجم، ٦٠&nbsp;مجم: ٠٫٠٣٦&nbsp;مجم، ٩٠&nbsp;مجم: ٠٫٠٥٤&nbsp;مجم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أوبادراي أخضر (٣٠&nbsp;مجم: ٧٫٢٠&nbsp;مجم، ٦٠&nbsp;مجم: ١٤٫٤٠&nbsp;مجم، ٩٠&nbsp;مجم: ٢١٫٦٠&nbsp;مجم) (يحتوي على لاكتوز أحادي الماء، هيبروميلوز، ثاني أوكسيد التيتانيوم (E۱٧۱&rlm;)&rlm;، جلسرول ثلاثي الاسيتات، FD&amp;C blue&lrm;&rlm; (E۱٣٢&rlm;)&rlm;، أوكسيد الحديد الأصفر (E۱٧٢&rlm;)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أوبادراي شفاف (٣٠&nbsp;مجم: ٢٫٧٠&nbsp;مجم، ٦٠&nbsp;مجم: ٥٫٤٠&nbsp;مجم، ٩٠&nbsp;مجم: ٨٫١٠&nbsp;مجم) (يحتوي على هيبروميلوز، وماكروقول).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">أقراص مغلفة خضراء فاتحة اللون، بيضاوية الشكل محفور على وجه منها ٣٠، ٦٠ أو ٩٠ وعلى الوجه الآخر &#39;AMG&#39;</p><p>&nbsp;</p><p dir="RTL">أقراص ۳٠&nbsp;مجم بطول حوالي ٩٫٧&nbsp;مم وعرض ٦٫۰&nbsp;مم.</p><p dir="RTL">أقراص ٦٠&nbsp;مجم بطول حوالي ۱٢٫٢&nbsp;مم وعرض ٧٫٦&nbsp;مم.</p><p dir="RTL">أقراص ٩٠&nbsp;مجم بطول حوالي ۱۳٫٩&nbsp;مم وعرض ۸٫٧&nbsp;مم.</p><p>&nbsp;</p><p dir="RTL">يتوفر ممبارا في شكل أقراص مغلفة في قصديرية تحتوي على ٣٠&nbsp;مجم، ٦٠&nbsp;مجم أو ٩٠&nbsp;مجم. ويكون بداخل كل علبة إما ١٤ أو ٢٨ أو ٨٤ قرصا.</p><p>&nbsp;</p><p dir="RTL">لا يتم تسويق كل أحجام العبوات.</p><p dir="RTL">لا يتم تسويق كل الأشكال الصيدلانية.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>صاحب ترخيص التسويق والمصنع:</strong></p><p dir="RTL">‪Amgen Europe B.V.</p><p dir="RTL">Minervum 7061</p><p dir="RTL">4817&nbsp;ZK Breda</p><p dir="RTL">هولندا</p><p dir="RTL"><strong>موقع التصنیع الأولي</strong></p><p dir="RTL">Patheon Inc., Toronto Region Operations</p><p dir="RTL">2100&nbsp;Syntex Court</p><p dir="RTL">Mississauga</p><p dir="RTL">Ontario</p><p dir="RTL">L5N 7K9</p><p dir="RTL">كندا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            آخر مراجعة لهذه النشرة بتاريخ أغسطس ٢٠۱٧.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Mimpara 30 mg film coated tablets.
Mimpara 60 mg film coated tablets.
Mimpara 90 mg film coated tablets.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet contains 30 mg cinacalcet (as hydrochloride).
Each tablet contains 60 mg cinacalcet (as hydrochloride).
Each tablet contains 90 mg cinacalcet (as hydrochloride).

Excipient with known effect:

Mimpara 30 mg film coated tablets
Each 30 mg tablet contains 2.74 mg of lactose.

Mimpara 60 mg film coated tablets
Each 60 mg tablet contains 5.47 mg of lactose.

Mimpara 90 mg film coated tablets
Each 90 mg tablet contains 8.21 mg of lactose.

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film coated tablet (tablet).

Mimpara 30 mg film coated tablets

Light green (approximately 9.7 mm long and 6.0 mm wide), oval, film coated tablet marked “AMG” on one side and “30” on the other.

Mimpara 60 mg film coated tablets

Light green, oval (approximately 12.2 mm long and 7.6 mm wide), film coated tablet marked “AMG” on one side and “60” on the other.

Mimpara 90 mg film coated tablets

Light green, oval (approximately 13.9 mm long and 8.7 mm wide), film coated tablet marked “AMG” on one side and “90” on the other.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>Treatment of secondary hyperparathyroidism (HPT) in patients with end‑stage renal disease (ESRD) on maintenance dialysis therapy.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p><em>&nbsp;</em></p><p>Refer to section 4.8 d)</p><p><em>&nbsp;</em></p><p>Mimpara may be used as part of a therapeutic regimen including phosphate binders and/or vitamin D sterols, as appropriate (see section 5.1).</p><p>&nbsp;</p><p><u>Parathyroid carcinoma and primary hyperparathyroidism</u></p><p>&nbsp;</p><p>Reduction of hypercalcaemia in patients with:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; parathyroid carcinoma.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; primary HPT for whom parathyroidectomy would be indicated on the basis of serum calcium levels (as defined by relevant treatment guidelines), but in whom parathyroidectomy is not clinically appropriate or is contraindicated.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Secondary hyperparathyroidism</u></p><p>&nbsp;</p><p><em>Adults and elderly (&gt;&nbsp;65&nbsp;years)</em></p><p><u>&nbsp;</u></p><p>The recommended starting dose for adults is 30&nbsp;mg once per day. Mimpara should be titrated every 2&nbsp;to 4&nbsp;weeks to a maximum dose of 180&nbsp;mg once daily to achieve a target parathyroid hormone (PTH) in dialysis patients of between 150‑300&nbsp;pg/mL (15.9‑31.8&nbsp;pmol/L) in the intact PTH (iPTH) assay. PTH levels should be assessed at least 12&nbsp;hours after dosing with Mimpara. Reference should be made to current treatment guidelines.</p><p>&nbsp;</p><p>PTH should be measured 1 to 4&nbsp;weeks after initiation or dose adjustment of Mimpara<em>. </em>PTH should be monitored approximately every 1‑3&nbsp;months during maintenance. Either the intact PTH (iPTH) or bio‑intact PTH (biPTH) may be used to measure PTH levels; treatment with Mimpara does not alter the relationship between iPTH and biPTH.</p><p>&nbsp;</p><p><em>Dose </em><em>adjustment based on serum calcium levels</em></p><p>Corrected serum calcium should be measured and monitored and should be at or above the lower limit of the normal range prior to administration of first dose of Mimpara (see section 4.4). The normal calcium range may differ depending on the methods used by your local laboratory.</p><p>&nbsp;</p><p>&nbsp;</p><p>During dose titration, serum calcium levels should be monitored frequently, and within 1&nbsp;week of initiation or dose adjustment of Mimpara. Once the maintenance dose has been established, serum calcium should be measured approximately monthly. In the event that corrected serum calcium levels fall below 8.4&nbsp;mg/dL (2.1&nbsp;mmol/L) and/or symptoms of hypocalcaemia occur the following management is recommended: &nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:618px"><thead><tr><td style="vertical-align:top"><p><strong>Corrected serum calcium level or clinical symptoms of hypocalcaemia</strong></p></td><td style="vertical-align:top"><p><strong>Recommendations</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>&lt;&nbsp;8.4&nbsp;mg/dL (2.1&nbsp;mmol/L) and &gt;&nbsp;7.5&nbsp;mg/dL (1.9&nbsp;mmol/L), or in the presence of clinical symptoms of hypocalcaemia</p></td><td style="vertical-align:top"><p>Calcium‑containing phosphate binders, vitamin D sterols and/or adjustment of dialysis fluid calcium concentrations can be used to raise serum calcium according to clinical judgment.</p></td></tr><tr><td style="vertical-align:top"><p>&lt;&nbsp;8.4&nbsp;mg/dL (2.1&nbsp;mmol/L) and &gt;&nbsp;7.5&nbsp;mg/dL (1.9&nbsp;mmol/L) or persistent symptoms of hypocalcaemia despite attempts to increase serum calcium</p></td><td style="vertical-align:top"><p>Reduce or withhold dose of Mimpara.</p></td></tr><tr><td style="vertical-align:top"><p>&le;&nbsp;7.5&nbsp;mg/dL (1.9&nbsp;mmol/L) or persistent symptoms of hypocalcaemia and vitamin D cannot be increased</p></td><td style="vertical-align:top"><p>Withhold administration of Mimpara until serum calcium levels reach 8.0&nbsp;mg/dL (2.0&nbsp;mmol/L) and/or symptoms of hypocalcaemia have resolved.</p><p>Treatment should be reinitiated using the next lowest dose of Mimpara.</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>&nbsp;</u></em></p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>Refer to section 4.8 d)</p><p><em>&nbsp;</em></p><p><u>Switch from etelcalcetide to Mimpara</u></p><p>&nbsp;</p><p>The switch from etelcalcetide to Mimpara and the appropriate wash out period has not been studied in patients. In patients who have discontinued etelcalcetide, Mimpara should not be initiated until at least three subsequent haemodialysis sessions have been completed, at which time serum calcium should be measured. Ensure serum calcium levels are within the normal range before Mimpara is initiated (see sections&nbsp;4.4 and 4.8).</p><p>&nbsp;</p><p><u>Parathyroid carcinoma and primary hyperparathyroidism</u></p><p>&nbsp;</p><p><em>Adults and elderly (&gt;&nbsp;65&nbsp;years)</em></p><p>&nbsp;</p><p>The recommended starting dose of Mimpara for adults is 30&nbsp;mg twice per day. The dose of Mimpara should be titrated every 2 to 4&nbsp;weeks through sequential doses of 30&nbsp;mg twice daily, 60&nbsp;mg twice daily, 90&nbsp;mg twice daily, and 90&nbsp;mg three or four times daily as necessary to reduce serum calcium concentration to or below the upper limit of normal. The maximum dose used in clinical trials was 90&nbsp;mg four times daily.</p><p>&nbsp;</p><p>Serum calcium should be measured within 1&nbsp;week after initiation or dose adjustment of Mimpara. Once maintenance dose levels have been established, serum calcium should be measured every 2 to 3&nbsp;months. After titration to the maximum dose of Mimpara, serum calcium should be periodically monitored; if clinically relevant reductions in serum calcium are not maintained, discontinuation of Mimpara therapy should be considered (see section 5.1).</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p><em>&nbsp;</em></p><p>Refer to section 4.8 d)</p><p>&nbsp;</p><p><u>Hepatic impairment</u></p><p>&nbsp;</p><p>No change in starting dose is necessary. Mimpara should be used with caution in<em> </em>patients with moderate to severe hepatic impairment and treatment should be closely monitored during dose titration and continued treatment (see sections 4.4 and 5.2).</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>&nbsp;</p><p>For oral use.</p><p>Tablets should be taken whole and should not be chewed, crushed or divided.</p><p>&nbsp;</p><p>It is recommended that Mimpara be taken with food or shortly after a meal, as studies have shown that bioavailability of cinacalcet is increased when taken with food (see section 5.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Hypocalcaemia (see sections 4.2 and 4.4).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Serum calcium</u></p><p>&nbsp;</p><p>Life threatening events and fatal outcomes associated with hypocalcaemia have been reported in adult and paediatric patients treated with Mimpara. Manifestations of hypocalcaemia may include paraesthesias, myalgias, cramping, tetany and convulsions. Decreases in serum calcium can also prolong the QT interval, potentially resulting in ventricular arrhythmia secondary to hypocalcaemia. Cases of QT prolongation and ventricular arrhythmia have been reported in patients treated with cinacalcet (see section 4.8). Caution is advised in patients with other risk factors for QT prolongation such as patients with known congenital long QT syndrome or patients receiving medicinal products known to cause QT prolongation.</p><p>&nbsp;</p><p>Since cinacalcet lowers serum calcium, patients should be monitored carefully for the occurrence of hypocalcaemia (see section 4.2). Serum calcium should be measured within 1 week after initiation or dose adjustment of Mimpara.</p><p><u>&nbsp;</u></p><p>Mimpara treatment should not be initiated in patients with a serum calcium (corrected for albumin) below the lower limit of the normal range.</p><p>&nbsp;</p><p>In CKD patients receiving dialysis who were administered Mimpara, approximately 30% of patients had at least one serum calcium value less than 7.5&nbsp;mg/dL (1.9&nbsp;mmol/L).</p><p><u>&nbsp;</u></p><p><em>Paediatric population</em></p><p><em>&nbsp;</em></p><p><em>&nbsp;</em></p><p><em>&nbsp;</em></p><p>Refer to section 4.8 d)</p><p><u>&nbsp;</u></p><p><em>CKD patients not on dialysis</em></p><p>Cinacalcet is not indicated for CKD patients not on dialysis. Investigational studies have shown that CKD patients not on dialysis treated with cinacalcet have an increased risk for hypocalcaemia (serum calcium levels &lt;&nbsp;8.4&nbsp;mg/dl [2.1&nbsp;mmol/l]) compared with cinacalcet‑treated CKD patients on dialysis, which may be due to lower baseline calcium levels and/or the presence of residual kidney function.</p><p><u>&nbsp;</u></p><p><u>Seizures</u></p><p>&nbsp;</p><p>Cases of seizures have been reported in patients treated with Mimpara (see section 4.8). The threshold for seizures is lowered by significant reductions in serum calcium levels. Therefore, serum calcium levels should be closely monitored in patients receiving Mimpara, particularly in patients with a history of a seizure disorder.</p><p>&nbsp;</p><p><u>Hypotension and/or worsening heart failure</u></p><p>&nbsp;</p><p>Cases of hypotension and/or worsening heart failure have been reported in patients with impaired cardiac function, in which a causal relationship to cinacalcet could not be completely excluded and may be mediated by reductions in serum calcium levels. (See section 4.8).</p><p>&nbsp;</p><p><u>Co-administration with other medicinal products</u></p><p><u>&nbsp;</u></p><p>Administer Mimpara with caution in patients receiving any other medicinal products known to lower serum calcium. Closely monitor serum calcium (see section 4.5).</p><p>&nbsp;</p><p>Patients receiving Mimpara should not be given etelcalcetide. Concurrent administration may result in severe hypocalcaemia.</p><p>&nbsp;</p><p><u>General </u></p><p>&nbsp;</p><p>Adynamic bone disease may develop if PTH levels are chronically suppressed below approximately 1.5 times the upper limit of normal with the iPTH assay. If PTH levels decrease below the recommended target range in patients treated with Mimpara, the dose of Mimpara and/or vitamin D sterols should be reduced or therapy discontinued.</p><p>&nbsp;</p><p><u>Testosterone levels</u></p><p>&nbsp;</p><p>Testosterone levels are often below the normal range in patients with end‑stage renal disease. In a clinical study of adult ESRD patients on dialysis, free testosterone levels decreased by a median of 31.3% in the Mimpara‑treated patients and by 16.3% in the placebo‑treated patients after 6&nbsp;months of treatment. An open‑label extension of this study showed no further reductions in free and total testosterone concentrations over a period of 3&nbsp;years in Mimpara‑treated patients. The clinical significance of these reductions in serum testosterone is unknown.</p><p>&nbsp;</p><p><u>Hepatic impairment</u></p><p>&nbsp;</p><p>Due to the potential for 2- to 4- fold higher plasma levels of cinacalcet in patients with moderate to severe hepatic impairment (Child‑Pugh classification), Mimpara should be used with caution in these patients and treatment should be closely monitored (see sections 4.2 and 5.2).</p><p>&nbsp;</p><p><u>Lactose</u></p><p>&nbsp;</p><p>Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose‑galactose malabsorption should not take this medicine.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Medicinal products known to reduce serum calcium</u></p><p><u>&nbsp;</u></p><p>Concurrent administration of other medicinal products known to reduce serum calcium and Mimpara may result in an increased risk of hypocalcaemia (see section 4.4). Patients receiving Mimpara should not be given etelcalcetide (see section 4.4).</p><p>&nbsp;</p><p><u>Effect of other medications on cinacalcet</u></p><p>&nbsp;</p><p>Cinacalcet is metabolised in part by the enzyme CYP3A4. Co‑administration of 200&nbsp;mg bid ketoconazole, a strong inhibitor of CYP3A4, caused an approximate 2‑fold increase in cinacalcet levels. Dose adjustment of Mimpara may be required if a patient receiving Mimpara initiates or discontinues therapy with a strong inhibitor (e.g. ketoconazole, itraconazole, telithromycin, voriconazole, ritonavir) or inducer (e.g. rifampicin) of this enzyme.</p><p>&nbsp;</p><p><em>In vitro</em> data indicate that cinacalcet is in part metabolised by CYP1A2. Smoking induces CYP1A2; the clearance of cinacalcet was observed to be 36‑38% higher in smokers than non‑smokers. The effect of CYP1A2 inhibitors (e.g. fluvoxamine, ciprofloxacin) on cinacalcet plasma levels has not been studied. Dose adjustment may be necessary if a patient starts or stops smoking or when concomitant treatment with strong CYP1A2 inhibitors is initiated or discontinued.</p><p>&nbsp;</p><p><em>Calcium carbonate</em>: Co‑administration of calcium carbonate (single 1,500&nbsp;mg dose) did not alter the pharmacokinetics of cinacalcet.</p><p>&nbsp;</p><p><em>Sevelamer</em>: Co‑administration of sevelamer (2,400&nbsp;mg tid) did not affect the pharmacokinetics of cinacalcet.</p><p>&nbsp;</p><p><em>Pantoprazole</em>: Co‑administration of pantoprazole (80&nbsp;mg od) did not alter the pharmacokinetics of cinacalcet.</p><p>&nbsp;</p><p><u>Effect of cinacalcet on other medications</u></p><p>&nbsp;</p><p>Medicinal products metabolised by the enzyme P450 2D6 (CYP2D6): Cinacalcet is a strong inhibitor of CYP2D6. Dose adjustments of concomitant medicinal products may be required when Mimpara is administered with individually titrated, narrow therapeutic index substances that are predominantly metabolised by CYP2D6 (e.g. flecainide, propafenone, metoprolol, desipramine, nortriptyline, clomipramine).</p><p>&nbsp;</p><p><em>Desipramine</em>: Concurrent administration of 90&nbsp;mg cinacalcet once daily with 50&nbsp;mg desipramine, a tricyclic antidepressant metabolised primarily by CYP2D6, significantly increased desipramine exposure 3.6‑fold (90% CI 3.0, 4.4) in CYP2D6 extensive metabolisers.</p><p>&nbsp;</p><p><em>Dextromethorphan:</em> Multiple doses of 50&nbsp;mg cinacalcet increased the AUC of 30&nbsp;mg dextromethorphan (metabolised primarily by CYP2D6) by 11-fold in CYP2D6 extensive metabolisers.</p><p>&nbsp;</p><p><em>Warfarin</em>: Multiple oral doses of cinacalcet did not affect the pharmacokinetics or pharmacodynamics (as measured by prothrombin time and clotting factor VII) of warfarin.</p><p>&nbsp;</p><p>The lack of effect of cinacalcet on the pharmacokinetics of R‑and S‑warfarin and the absence of auto‑induction upon multiple dosing in patients indicates that cinacalcet is not an inducer of CYP3A4, CYP1A2 or CYP2C9 in humans.</p><p>&nbsp;</p><p><em>Midazolam</em>: Co‑administration of cinacalcet (90&nbsp;mg) with orally administered midazolam (2&nbsp;mg), a CYP3A4 and CYP3A5 substrate, did not alter the pharmacokinetics of midazolam. These data suggest that cinacalcet would not affect the pharmacokinetics of those classes of medicines that are metabolised by CYP3A4 and CYP3A5, such as certain immunosuppressants, including cyclosporine and tacrolimus.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>&nbsp;</p><p>There are no clinical data from the use of cinacalcet in pregnant women. Animal studies do not indicate direct harmful effects with respect to pregnancy, parturition or postnatal development. No embryonal/foetal toxicities were seen in studies in pregnant rats and rabbits with the exception of decreased foetal body weights in rats at doses associated with maternal toxicities (see section 5.3). Mimpara should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>&nbsp;</p><p>It is not known whether cinacalcet is excreted in human milk. Cinacalcet is excreted in the milk of lactating rats with a high milk to plasma ratio. Following careful benefit/risk assessment, a decision should be made to discontinue either breast‑feeding or treatment with Mimpara.</p><p>&nbsp;</p><p><u>Fertility</u></p><p><u>&nbsp;</u></p><p>There are no clinical data relating to the effect of cinacalcet on fertility. There were no effects on fertility in animal studies.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Dizziness and seizures, which may have major influence on the ability to drive and use machines, have been reported by patients taking Mimpara (see section 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong></p><p>&nbsp;</p><p>a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Summary of the safety profile</p><p><u>&nbsp;</u></p><p><u>Secondary hyperparathyroidism, parathyroid carcinoma and primary hyperparathyroidism</u></p><p>&nbsp;</p><p>Based on available data from patients receiving cinacalcet in placebo controlled studies and single‑arm studies the most commonly reported adverse reactions were nausea and vomiting. Nausea and vomiting were mild to moderate in severity and transient in nature in the majority of patients. Discontinuation of therapy as a result of undesirable effects was mainly due to nausea and vomiting.</p><p>&nbsp;</p><p>b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tabulated list of adverse reactions</p><p>&nbsp;</p><p>Adverse reactions, considered at least possibly attributable to cinacalcet treatment in the placebo controlled studies and single-arm studies based on best evidence assessment of causality are listed below using the following convention: very common (&ge;&nbsp;1/10); common (&ge;&nbsp;1/100 to &lt;&nbsp;1/10); uncommon (&ge;&nbsp;1/1,000 to &lt;&nbsp;1/100); rare (&ge;&nbsp;1/10,000 to &lt;&nbsp;1/1,000); very rare (&lt;&nbsp;1/10,000).</p><p>&nbsp;</p><p>Incidence of adverse reactions from controlled clinical studies and post-marketing experience are:</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td style="vertical-align:top"><p><strong>MedDRA system organ class</strong></p></td><td style="vertical-align:top"><p><strong>Subject incidence</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reaction</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Common<sup>*</sup></p></td><td style="vertical-align:top"><p>Hypersensitivity reactions</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>Common</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anorexia</p><p>Decreased appetite</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Common</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Seizures<sup>&dagger;</sup></p><p>Dizziness</p><p>Paraesthesia</p><p>Headache</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>Not known<sup>*</sup></p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Worsening heart failure<sup>&dagger;</sup></p><p>QT prolongation and ventricular arrhythmia secondary to hypocalcaemia<sup>&dagger;</sup></p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Hypotension</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>Common</p><p>&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Upper respiratory infection</p><p>Dyspnoea</p><p>Cough</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Very common</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Nausea</p><p>Vomiting</p></td></tr><tr><td style="vertical-align:top"><p>Common</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dyspepsia</p><p>Diarrhoea</p><p>Abdominal pain</p><p>Abdominal pain &ndash; upper</p><p>Constipation</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Rash</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>Common</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Myalgia</p><p>Muscle spasms</p><p>Back pain</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Asthenia</p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>Common</p><p>&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypocalcaemia<sup>&dagger;</sup></p><p>Hyperkalaemia</p><p>Reduced testosterone levels<sup>&dagger;</sup></p></td></tr></tbody></table><p><sup>&dagger;</sup>see section 4.4</p><p><sup>*</sup>see section c</p><p>&nbsp;</p><p>c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Description of selected adverse reactions</p><p>&nbsp;</p><p><em>Hypersensitivity reactions</em></p><p>&nbsp;</p><p>Hypersensitivity reactions including angioedema and urticaria have been identified during post -marketing use of Mimpara. The frequencies of the individual preferred terms including angioedema and urticaria cannot be estimated from available data.</p><p>&nbsp;</p><p><em>Hypotension and/or worsening heart failure</em></p><p>&nbsp;</p><p>There have been reports of idiosyncratic cases of hypotension and/or worsening heart failure in cinacalcet treated patients with impaired cardiac function in post-marketing safety surveillance, the frequencies of which cannot be estimated from available data.</p><p>&nbsp;</p><p><em>QT prolongation and ventricular arrhythmia secondary to hypocalcaemia</em></p><p>&nbsp;</p><p>QT prolongation and ventricular arrhythmia secondary to hypocalcaemia have been identified during post-marketing use of Mimpara, the frequencies of which cannot be estimated from available data (see section 4.4).</p><p>&nbsp;</p><p>d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Paediatric population</p><p>&nbsp;</p><p>&nbsp;</p><p>Cinacalcet HCl is not indicated for use in paediatric patients.</p><p>&nbsp;</p><p>A fatal outcome was reported in a paediatric clinical trial patient with severe hypocalcaemia.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p><u>&nbsp;</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions to their local representative.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>To report any side effects:</p><p>Saudi Arabia:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance Centre (NPC):</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/</p><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Doses titrated up to 300&nbsp;mg once daily have been administered to patients receiving dialysis without adverse outcome.</p><p>&nbsp;</p><p>Overdose of Mimpara may lead to hypocalcaemia. In the event of overdose, patients should be monitored for signs and symptoms of hypocalcaemia, and treatment should be symptomatic and supportive. Since cinacalcet is highly protein‑bound, haemodialysis is not an effective treatment for overdose.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Calcium homeostasis, anti‑parathyroid agents. ATC code: H05BX01.</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p>The calcium sensing receptor on the surface of the chief cell of the parathyroid gland is the principal regulator of PTH secretion. Cinacalcet is a calcimimetic agent which directly lowers PTH levels by increasing the sensitivity of the calcium sensing receptor to extracellular calcium. The reduction in PTH is associated with a concomitant decrease in serum calcium levels.</p><p>&nbsp;</p><p>Reductions in PTH levels correlate with cinacalcet concentration.</p><p>&nbsp;</p><p>After steady state is reached, serum calcium concentrations remain constant over the dosing interval.</p><p>&nbsp;</p><p><u>Secondary hyperparathyroidism </u></p><p>&nbsp;</p><p>Three, 6‑month, double‑blind, placebo‑controlled clinical studies were conducted in ESRD patients with uncontrolled secondary HPT receiving dialysis (n&nbsp;=&nbsp;1,136). Demographic and baseline characteristics were representative of the dialysis patient population with secondary HPT. Mean baseline iPTH concentrations across the 3 studies were 733 and 683&nbsp;pg/mL (77.8 and 72.4&nbsp;pmol/L) for the cinacalcet and placebo groups, respectively. 66% of patients were receiving vitamin&nbsp;D sterols at study entry, and &gt;&nbsp;90% were receiving phosphate binders. Significant reductions in iPTH, serum calcium‑phosphorus product (Ca x P), calcium, and phosphorus were observed in the cinacalcet‑treated patients compared with placebo‑treated patients receiving standard of care, and the results were consistent across the 3 studies. In each of the studies, the primary endpoint (proportion of patients with an iPTH&nbsp;&le;&nbsp;250&nbsp;pg/mL(&le;&nbsp;26.5&nbsp;pmol/L)) was achieved by 41%, 46%, and 35% of patients receiving cinacalcet, compared with 4%, 7%, and 6% of patients receiving placebo. Approximately 60% of cinacalcet‑treated patients achieved a &ge;&nbsp;30% reduction in iPTH levels, and this effect was consistent across the spectrum of baseline iPTH levels. The mean reductions in serum Ca x P, calcium, and phosphorus were 14%, 7% and 8%, respectively.</p><p>&nbsp;</p><p>Reductions in iPTH and Ca x P were maintained for up to 12&nbsp;months of treatment. Cinacalcet decreased iPTH and Ca x P, calcium and phosphorus levels regardless of baseline iPTH or Ca x P level, dialysis modality (PD versus HD), duration of dialysis, and whether or not vitamin D sterols were administered.</p><p>&nbsp;</p><p>Reductions in PTH were associated with non‑significant reductions of bone metabolism markers (bone specific alkaline phosphatase, N‑telopeptide, bone turnover and bone fibrosis). In post‑hoc analyses of pooled data from 6 and 12&nbsp;months clinical studies, Kaplan‑Meier estimates of bone fracture and parathyroidectomy were lower in the cinacalcet group compared with the control group.</p><p>&nbsp;</p><p>Investigational studies in patients with CKD and secondary HPT not undergoing dialysis indicated that cinacalcet reduced PTH levels to a similar extent as in patients with ESRD and secondary HPT receiving dialysis. However, efficacy, safety, optimal doses and treatment targets have not been established in treatment of predialytic renal failure patients. These studies show that CKD patients not undergoing dialysis treated with cinacalcet have an increased risk for hypocalcaemia compared with cinacalcet‑treated ESRD patients receiving dialysis, which may be due to lower baseline calcium levels and/or the presence of residual kidney function.</p><p>&nbsp;</p><p>EVOLVE (EValuation Of Cinacalcet Therapy to Lower CardioVascular Events) was a randomised, double-blind clinical study evaluating cinacalcet versus placebo for the reduction of the risk of all-cause mortality and cardiovascular events in 3,883 patients with secondary HPT and CKD receiving dialysis. The study did not meet its primary objective of demonstrating a reduction in risk of all-cause mortality or cardiovascular events including myocardial infarction, hospitalisation for unstable angina, heart failure or peripheral vascular event (HR 0.93; 95% CI: 0.85, 1.02; p = 0.112). After adjusting for baseline characteristics in a secondary analysis, the HR for the primary composite endpoint was 0.88; 95% CI: 0.79, 0.97.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Parathyroid carcinoma and Primary Hyperparathyroidism</u></p><p>&nbsp;</p><p>In one study, 46 patients (29 with parathyroid carcinoma and 17 with primary HPT and severe hypercalcaemia (who had failed or had contraindications to parathyroidectomy) received cinacalcet for up to 3&nbsp;years (mean of 328&nbsp;days for patients with parathyroid carcinoma and mean of 347&nbsp;days for patients with primary HPT). Cinacalcet was administered at doses ranging from 30&nbsp;mg twice daily to 90&nbsp;mg four times daily. The primary endpoint of the study was a reduction of serum calcium of &ge;&nbsp;1&nbsp;mg/dL (&ge;&nbsp;0.25&nbsp;mmol/L). In patients with parathyroid carcinoma, mean serum calcium declined from 14.1&nbsp;mg/dL to 12.4&nbsp;mg/dL (3.5&nbsp;mmol/L to 3.1&nbsp;mmol/L), while in patients with primary HPT, serum calcium levels declined from 12.7&nbsp;mg/dL to 10.4&nbsp;mg/dL (3.2&nbsp;mmol/L to 2.6&nbsp;mmol/L). Eighteen (18) of 29&nbsp;patients (62%) with parathyroid carcinoma and 15 of 17 subjects (88%) with primary HPT achieved a reduction in serum calcium of &ge;&nbsp;1&nbsp;mg/dL (&ge;&nbsp;0.25&nbsp;mmol/L).</p><p>&nbsp;</p><p>In a 28&nbsp;week placebo-controlled study, 67&nbsp; patients with primary HPT who met criteria for parathyroidectomy on the basis of corrected total serum calcium (&gt;&nbsp;11.3&nbsp;mg/dL (2.82&nbsp;mmol/L) but &le;&nbsp;12.5&nbsp;mg/dL (3.12&nbsp;mmol/L), but who were unable to undergo parathyroidectomy were included. Cinacalcet was initiated at a dose of 30&nbsp;mg twice daily and titrated to maintain a corrected total serum calcium concentration within the normal range. A significantly higher percentage of cinacalcet-treated patients achieved mean corrected total serum calcium concentration &le;&nbsp;10.3&nbsp;mg/dL (2.57&nbsp;mmol/L) and &ge;&nbsp;1&nbsp;mg/dL (0.25&nbsp;mmol/L) decrease from baseline in mean corrected total serum calcium concentration, when compared with the placebo-treated patients (75.8% versus 0% and 84.8% versus 5.9% respectively).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>&nbsp;</p><p>After oral administration of Mimpara, maximum plasma cinacalcet concentration is achieved in approximately 2&nbsp;to 6&nbsp;hours. Based on between‑study comparisons, the absolute bioavailability of cinacalcet in fasted subjects has been estimated to be about 20‑25%. Administration of Mimpara with food results in an approximate 50&ndash;80% increase in cinacalcet bioavailability. Increases in plasma cinacalcet concentration are similar, regardless of the fat content of the meal.</p><p>&nbsp;</p><p>At doses above 200&nbsp;mg, the absorption was saturated probably due to poor solubility.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>&nbsp;</p><p>The volume of distribution is high (approximately 1,000&nbsp;litres), indicating extensive distribution. Cinacalcet is approximately 97% bound to plasma proteins and distributes minimally into red blood cells.</p><p>&nbsp;</p><p>After absorption, cinacalcet concentrations decline in a biphasic fashion with an initial half‑life of approximately 6&nbsp;hours and a terminal half‑life of 30 to 40&nbsp;hours. Steady state levels of cinacalcet are achieved within 7&nbsp;days with minimal accumulation. The pharmacokinetics of cinacalcet does not change over time.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>&nbsp;</p><p>Cinacalcet is metabolised by multiple enzymes, predominantly CYP3A4 and CYP1A2 (the contribution of CYP1A2 has not been characterised clinically). The major circulating metabolites are inactive.</p><p>&nbsp;</p><p>Based on <em>in vitro</em> data, cinacalcet is a strong inhibitor of CYP2D6, but is neither an inhibitor of other CYP enzymes at concentrations achieved clinically, including CYP1A2, CYP2C8, CYP2C9, CYP2C19, and CYP3A4 nor an inducer of CYP1A2, CYP2C19 and CYP3A4.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>&nbsp;</p><p>After administration of a 75&nbsp;mg radiolabelled dose to healthy volunteers, cinacalcet was rapidly and extensively metabolised by oxidation followed by conjugation. Renal excretion of metabolites was the prevalent route of elimination of radioactivity. Approximately 80% of the dose was recovered in the urine and 15% in the faeces.</p><p>&nbsp;</p><p><u>Linearity/non-linearity</u></p><p>&nbsp;</p><p>The AUC and C<sub>max</sub> of cinacalcet increase approximately linearly over the dose range of 30 to 180&nbsp;mg once daily.</p><p>&nbsp;</p><p><u>Pharmacokinetic/pharmacodynamic relationship(s)</u></p><p>&nbsp;</p><p>Soon after dosing, PTH begins to decrease until a nadir at approximately 2 to 6&nbsp;hours post-dose, corresponding with cinacalcet C<sub>max</sub>. Thereafter, as cinacalcet levels begin to decline, PTH levels increase until 12&nbsp;hours post‑dose, and then PTH suppression remains approximately constant to the end of the once‑daily dosing interval. PTH levels in Mimpara clinical trials were measured at the end of the dosing interval.</p><p>&nbsp;</p><p><em>Elderly:</em> There are no clinically relevant differences due to age in the pharmacokinetics of cinacalcet.</p><p>&nbsp;</p><p><em>Renal insufficiency:</em> The pharmacokinetic profile of cinacalcet in patients with mild, moderate, and severe renal insufficiency, and those on haemodialysis or peritoneal dialysis is comparable to that in healthy volunteers.</p><p>&nbsp;</p><p><em>Hepatic insufficiency:</em> Mild hepatic impairment did not notably affect the pharmacokinetics of cinacalcet. Compared to subjects with normal liver function, average AUC of cinacalcet was approximately 2‑fold higher in subjects with moderate impairment and approximately 4‑fold higher in subjects with severe impairment. The mean half‑life of cinacalcet is prolonged by 33% and 70% in patients with moderate and severe hepatic impairment, respectively. Protein binding of cinacalcet is not affected by impaired hepatic function. Because doses are titrated for each subject based on safety and efficacy parameters, no additional dose adjustment is necessary for subjects with hepatic impairment (see sections 4.2 and 4.4).</p><p>&nbsp;</p><p><em>Gender:</em> Clearance of cinacalcet may be lower in women than in men. Because doses are titrated for each subject, no additional dose adjustment is necessary based on gender.</p><p>&nbsp;</p><p><em>Paediatric population</em><em>:</em> The pharmacokinetics of cinacalcet was studied in 12 paediatric patients (6- 17 years) with CKD receiving dialysis following a single. Oral. 15 mg dose. Men AUC and C<sub>max</sub> values (23.5 (range 7.22 to 77.2) ng*hr/mL and 7.26 (range 1.80 to 17.4) ng/mL, respectively) were withing approximately 30% of the means for AUC and C<sub>max</sub> values observed in a single study in healthy adults following a single 30 mg dose (33.6 (range 4.75 to 66.9) ng*hr/mL and 5.42 (range 1.41 to 12.7) ng/mL, respectively). Due to the limited data in paediatric subjects, the poptential for higher exposures in the lighter/ younger relative to heavier/older paediatric subjects for a given dose of cinacalcet cannot be excluded. The pharmacokinetics in paediatric subjects after multiple doses has not been established.</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Smoking: </em>Clearance of cinacalcet is higher in smokers than in non‑smokers, likely due to induction of CYP1A2‑mediated metabolism. If a patient stops or starts smoking, cinacalcet plasma levels may change and dose adjustment may be necessary.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cinacalcet was not teratogenic in rabbits when given at a dose of 0.4 times, on an AUC basis, the maximum human dose for secondary HPT (180&nbsp;mg daily). The non‑teratogenic dose in rats was&nbsp;4.4 times, on an AUC basis, the maximum dose for secondary HPT. There were no effects on fertility in males or females at exposures up to 4 times a human dose of 180&nbsp;mg/day (safety margins in the small population of patients administered a maximum clinical dose of 360&nbsp;mg daily would be approximately half those given above).</p><p>&nbsp;</p><p>In pregnant rats, there were slight decreases in body weight and food consumption at the highest dose. Decreased foetal weights were seen in rats at doses where dams had severe hypocalcaemia. Cinacalcet has been shown to cross the placental barrier in rabbits.</p><p>&nbsp;</p><p>Cinacalcet did not show any genotoxic or carcinogenic potential. Safety margins from the toxicology studies are small due to the dose‑limiting hypocalcaemia observed in the animal models. Cataracts and lens opacities were observed in the repeat dose rodent toxicology and carcinogenicity studies, but were not observed in dogs or monkeys or in clinical studies where cataract formation was monitored. Cataracts are known to occur in rodents as a result of hypocalcaemia.</p><p>&nbsp;</p><p>In <em>in vitro </em>studies, IC<sub>50</sub> values for the serotonin transporter and K<sub>ATP</sub> channels were found to be 7 and 12-fold greater, respectively, than the EC<sub>50</sub> for the calcium sensing receptor obtained under the same experimental conditions. The clinical relevance is unknown, however, the potential for cinacalcet to act on these secondary targets cannot be fully excluded.</p><p>&nbsp;</p><p>In toxicity studies in juvenile dogs, tremors secondary to decreased serum calcium, emesis, decreased body weight and body weight gain, decreased red cell mass, slight decreases in bone densitometry parameters, reversible widening of the growth plates of long bones, and histological lymphoid changes (restricted to the thoracic cavity and attributed to chronic emesis) were observed. All of these effects were seen at a systemic exposure, on an AUC basis, approximately equivalent to the exposure in patients at the maximum dose for secondary HPT.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p><u>Tablet core (30 mg)</u></p><p>&nbsp;</p><p>Pre‑gelatinised starch (maize) (12.02 mg), Microcrystalline cellulose (121.82 mg), Povidone (3.68 mg), Crospovidone (7.62 mg), Magnesium stearate (0.90 mg), Colloidal anhydrous silica (0.90 mg). &nbsp;</p><p>&nbsp;</p><p><u>Tablet core (60 mg)</u></p><p>Pre‑gelatinised starch (maize) (24.04 mg), Microcrystalline cellulose (243.64 mg), Povidone (7.36 mg), Crospovidone (15.24 mg), Magnesium stearate (1.80 mg), Colloidal anhydrous silica (1.80 mg).</p><p><u>Tablet core (90 mg)</u></p><p>Pre‑gelatinised starch (maize) (36.06 mg), Microcrystalline cellulose (365.46 mg), Povidone (11.04 mg), Crospovidone (22.86 mg), Magnesium stearate (2.70 mg), Colloidal anhydrous silica (2.70 mg).</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Tablet coat (30 mg)</u></p><p>&nbsp;</p><p>Carnauba wax (0.018 mg)</p><p>Opadry II green: (7.20 mg):&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (Lactose monohydrate, hypromellose, titanium dioxide (E171), glycerol triacetate, FD&amp;C Blue (E132), iron oxide yellow (E172))</p><p>Opadry clear: (2.70 mg):&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (Hypromellose, macrogol)</p><p>&nbsp;</p><p><u>Tablet coat (60 mg)</u></p><p>Carnauba wax (0.036 mg)</p><p>Opadry II green (14.40 mg): &nbsp;&nbsp;&nbsp; (Lactose monohydrate, hypromellose, titanium dioxide (E171), glycerol triacetate, FD&amp;C Blue (E132), iron oxide yellow (E172))</p><p>Opadry clear (5.40 mg):&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (Hypromellose, macrogol)</p><p>&nbsp;</p><p><u>Tablet coat (90 mg)</u></p><p>Carnauba wax (0.054 mg)</p><p>Opadry II green (21.60 mg): &nbsp;&nbsp;&nbsp; (Lactose monohydrate, hypromellose, titanium dioxide (E171), glycerol triacetate, FD&amp;C Blue (E132), iron oxide yellow (E172))</p><p>Opadry clear (8.10 mg):&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (Hypromellose, macrogol)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Blister: 5 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product does not require any special storage conditions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Aclar/PVC/PVAc/Aluminium blister containing 14 tablets. Pack size of 2&nbsp;blisters (28 tablets) per carton.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements for disposal.</p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Amgen Europe B.V.
Minervum 7061
4817 ZK Breda
The Netherlands

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                May 2019
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>